A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Summary

A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined with chemotherapy in subjects with newly-diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).

Eligibility

Inclusion Criteria:

1. Newly diagnosed Philadelphia chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
2. Expected survival of at least 3 months
3. ECOG ≤ 2
4. Adequate organ function

Exclusion Criteria:

1. A history of chronic myeloid leukemia (CML)
2. Clinical manifestations of central nervous system (CNS) leukemia or ALL extramedullary infiltration, except lymphadenopathy or hepatosplenomegaly
3. Previous or current clinical CNS diseases
4. Autoimmune diseases that may involve the CNS
5. Use of therapeutic doses of anticoagulants and/or antiplatelet agents; low doses of anticoagulants or antiplatelet agents are allowed
6. Use a therapeutic drug that has drug interaction with the investigational drug due to other diseases within 7 days or within 5 half-lives (whichever is shorter) prior to the first receipt of the investigational drug
7. Uncontrolled heart diseases
8. Any venous thromboembolism in the 6 months prior to randomization, including but not limited to deep vein thrombosis (DVT) or pulmonary embolism
9. Use of prohibited drugs
10. Disease or medical condition that is unstable or may affect its safety or compliance with the study
11. Use of medications known to cause prolonged QT interval
12. Active infections requiring systemic treatment
13. Disease that severely affects the oral administration and absorption of drugs, or an active gastrointestinal ulcer
14. Contraindications to the use of glucocorticoids
15. Bleeding disorders unrelated to ALL
16. Plan to undergo major surgery
17. Allergy to drug ingredients, excipients, or their analogues in the study
18. Female subjects who are pregnant or breastfeeding or expect to become pregnant during the study period
19. Other malignant tumors within 2 years
20. Any symptom or illness that may interfere with the evaluation of the efficacy and safety of the investigational drug, or any other condition or condition that is not appropriate for participation in the study

Conditions3

Interventions2

Locations16 sites

Find trials near these locations

Related trials

• A Study of Olverembatinib in SDH-deficient GIST. — Ascentage Pharma Group Inc.
• ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL — Institute of Hematology & Blood Diseases Hospital, China
• Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL — Institute of Hematology & Blood Diseases Hospital, China
• Newly-diagnosed Pediatric Ph-positive B-ALL Protocol — Institute of Hematology & Blood Diseases Hospital, China
• Olverembatinib for FGFR1-rearranged Neoplasms — The First Affiliated Hospital of Soochow University
• Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML — Ascentage Pharma Group Inc.
• The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP — Peking University People's Hospital
• Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL — First Affiliated Hospital of Zhejiang University

Browse More Trials